L3VLUP
ProSign in

LEGN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

LEGNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • LEGN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterLEGNLLY
Q3 20202 holders, $116m33 holders, $14.1bn
Q4 20203 holders, $123m29 holders, $17.3bn
Q1 20214 holders, $170m24 holders, $23.0bn
Q2 20214 holders, $178m24 holders, $27.8bn
Q3 20215 holders, $387m31 holders, $29.9bn
Q4 20216 holders, $401m31 holders, $34.7bn
Q1 20227 holders, $338m24 holders, $35.3bn
Q2 20229 holders, $993m33 holders, $42.7bn
Q3 20228 holders, $847m31 holders, $43.4bn
Q4 20229 holders, $1.1bn31 holders, $46.6bn
Q1 202310 holders, $1.2bn33 holders, $44.3bn
Q2 202311 holders, $2.5bn37 holders, $59.6bn
Q3 202312 holders, $2.4bn44 holders, $67.6bn
Q4 202311 holders, $2.1bn45 holders, $73.6bn
Q1 202410 holders, $2.1bn41 holders, $95.3bn
Q2 20248 holders, $1.6bn43 holders, $110bn
Q3 20249 holders, $1.8bn45 holders, $107bn
Q4 202410 holders, $523m46 holders, $93.9bn
Q1 20258 holders, $916m42 holders, $98.4bn
Q2 20256 holders, $1.1bn43 holders, $93.2bn
Q3 20255 holders, $1.1bn39 holders, $86.7bn
Q4 20256 holders, $679m41 holders, $123bn
Q1 20264 holders, $155m39 holders, $106bn
Q2 20265 holders, $1.0bn44 holders, $132bn
LEGN

Legend Biotech Corp

Holders
6
Reported value
$1.1bn
Buyers
6
Sellers
0

Breadth +6 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only LEGN (0)

None.

Only LLY (37)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, and 12 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →